Belite Bio to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company specializing in novel therapeutics for degenerative retinal diseases, has announced its participation in three major investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference (September 5, 8:00 am ET), the Morgan Stanley 23rd Annual Global Healthcare Conference (September 8, 5:35 pm ET), and the H.C. Wainwright 27th Annual Global Investment Conference (September 9, 8:00 am ET). All presentations will be available via webcast on the company's investor relations website, with replays archived for 90 days.

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details of the presentations are as follows:

• Cantor Global Healthcare Conference
  • September 5, 2025, at 8:00 am ET, fireside chat
• Morgan Stanley 23^rd Annual Global Healthcare Conference
  • September 8, 2025, at 5:35 pm ET, fireside chat
• H.C. Wainwright 27^th Annual Global Investment Conference
  • September 9, 2025, at 8:00 am ET, fireside chat

Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When is Belite Bio (BLTE) presenting at the Cantor Global Healthcare Conference 2025?

Belite Bio will present at the Cantor Global Healthcare Conference on September 5, 2025, at 8:00 am ET in a fireside chat format.

What time is Belite Bio's presentation at the Morgan Stanley Healthcare Conference 2025?

Belite Bio will present at the Morgan Stanley Global Healthcare Conference on September 8, 2025, at 5:35 pm ET in a fireside chat format.

How can investors access Belite Bio's conference presentations?

Investors can access the webcasts under the 'Events' tab on Belite Bio's investor relations website at investors.belitebio.com. Replays will be available for 90 days after each presentation.

What is Belite Bio's main business focus?

Belite Bio is a clinical-stage drug development company focused on developing novel therapeutics targeting degenerative retinal diseases with significant unmet medical needs.